This is a multicenter, Phase 2 study to assess the activity of tesevatinib in patients with recurrent glioblastoma.
A Phase 2, Multicenter Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma
Glioblastoma Recurrent Glioblastoma Brain Tumor
Open to people ages 18 years and up
ANC < 1.5 x109/L; Plt < 100 x109/L Hgb < 9.0 g/dL within 7 days prior to enrollment.The use of transfusion or other intervention to achieve Hb ≥ 9 g/dL is acceptable.
Has marked prolongation of QTc(F) interval at screening or baseline (QTc[F] interval
470 msec) using the Fridericia method of correction for heart rate.
We will not share your information with anyone other than the team in charge of this study. Submitting your contact information does not obligate you to participate in research.
The study team should get back to you in a few business days.
You will also receive an email with next steps. Check your junk/spam folder if needed.
If you do not hear from the study team, please call 888-689-8273 and tell them you’re interested in study number NCT02844439.
© The Regents of the University of California